Dr Behrenbruch is a co-founder of Telix and was appointed Managing Director and Group Chief Executive Officer on 3 January 2017. See above for further biographical details.
Mr Smith has more than 20 years of experience in executive finance and general management across a broad range of industries, including in life-sciences, for publicly listed, private, international and Australian government organisations. Prior to joining us, Darren was Global Chief Financial Officer and Company Secretary at Sirtex Medical Ltd (from June 2008 to March 2019).
Mr Valeix has more than 20 twenty years of pharmaceutical industry experience, including radiopharmaceuticals, gained in senior executive leadership roles across a broad range of therapeutic product areas. Previously, Richard worked (from January 2014 to April 2021) at Advanced Accelerator Applications (AAA), a Novartis Company, where he served in the roles of General Manager for France, Switzerland, Belgium, the Netherlands and Luxembourg, and Global Head of Marketing and Sales.
Dr Cade has more than 20 years experience as an industry physician spanning the fields of novel biotechnology, pharmaceuticals and medical devices. Prior to joining us, David held senior executive roles at Cochlear Ltd, where he served as Chief Medical Officer, and at Sirtex Medical Ltd, where he served also as Chief Medical Officer, and in other senior roles across the U.S., Europe and Australia, gaining deep experience in the Oncology, Interventional Radiology and Nuclear Medicine therapeutic areas.
Mr Stonecypher has more than 25 years of experience in the life science industry in research, development and commercialisation of novel human medicines. An expert in Regulatory Affairs and Quality, James is passionate about rapidly advancing innovative therapies for high unmet needs and improving access to medicine. James has held senior leadership roles at major and emerging biopharmaceutical companies in the U.S. and Europe, including Amgen, Allergan, Micromet, and BioNTech.
Ms Moran-Adams has more than 25 years of experience driving proactive, results-driven legal and compliance solutions worldwide, including 19 years’ experience in the pharmaceutical industry in various country, regional and global leadership roles. Prior to joining us, Lena was the Head of Legal and Business Conduct, Intercontinental at Gilead Sciences and a Global Head of Legal at Novartis. Lena is admitted to the bar and entitled to practise law in Australia, the UK and in New York.
Mr Richardson has more than 25 years of experience in the healthcare industry, including seven years focused in sales, marketing and business operations in the radiopharmaceutical segment. Immediately prior to joining us, Kevin was the Chief Operating Officer of UroShape Medical, a technology company which has developed and successfully commercialised a medical device for a large, undertreated segment in the women’s health market. Prior to this, he spent seven years in the Americas division of Sirtex Medical Ltd.
Mr Ortiz joined Telix with more than 20 years of pharmaceutical industry experience in a variety of roles, including in finance, business development, marketing and sales, as well as general management in Europe, Latin America and Asia. Prior to joining Telix, Raphaël worked at AAA, a Novartis Company, and most recently in the role of Asia-Pacific Cluster Head, setting up the radioligand therapy operations in the region.